Developing nonsteroidal anti-inflammatory drugs (NSAIDs) with decreased gastrointestinal (GI) toxicity.
NSAID-induced gastropathy is an important iatrogenic disorder that must be addressed in the development of NSAIDs. A scheme for clinical evaluation is described and salsalate is discussed as a prototype.